Biosig Technologies (NASDAQ:STEX) Issues Quarterly Earnings Results

Biosig Technologies (NASDAQ:STEX) issued its earnings results on Tuesday. The company reported ($8.23) earnings per share (EPS) for the quarter, FiscalAI reports.

Biosig Technologies Stock Up 7.7%

STEX traded up $0.08 on Tuesday, hitting $1.13. 2,357,100 shares of the company were exchanged, compared to its average volume of 2,051,001. Biosig Technologies has a fifty-two week low of $0.40 and a fifty-two week high of $14.11. The firm has a market capitalization of $200.84 million, a price-to-earnings ratio of -0.83 and a beta of 1.60. The business has a fifty day moving average price of $2.31.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Weiss Ratings assumed coverage on Biosig Technologies in a report on Friday, January 23rd. They set a “sell (d-)” rating on the stock. Wall Street Zen raised Biosig Technologies from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Insider Activity

In other news, CIO Mitchell Young Williams purchased 51,511 shares of the firm’s stock in a transaction dated Friday, January 23rd. The shares were acquired at an average price of $3.03 per share, with a total value of $156,078.33. Following the purchase, the executive directly owned 1,051,511 shares of the company’s stock, valued at $3,186,078.33. The trade was a 5.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Morgan Lee Lekstrom purchased 20,000 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $50,000.00. Following the acquisition, the chairman owned 122,500 shares in the company, valued at approximately $306,250. This trade represents a 19.51% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 1,267,011 shares of company stock worth $3,825,628. Company insiders own 52.73% of the company’s stock.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.